980 related articles for article (PubMed ID: 32474885)
21. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
Dalamaga M; Karampela I; Mantzoros CS
Metabolism; 2020 Aug; 109():154282. PubMed ID: 32497535
[TBL] [Abstract][Full Text] [Related]
22. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?
Liu JM; Chi J
Exp Biol Med (Maywood); 2022 Feb; 247(4):330-337. PubMed ID: 35068219
[TBL] [Abstract][Full Text] [Related]
23. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
24. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
[TBL] [Abstract][Full Text] [Related]
25. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
Front Immunol; 2020; 11():1648. PubMed ID: 32754159
[TBL] [Abstract][Full Text] [Related]
26. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.
Loscocco GG
Int J Hematol; 2020 Jul; 112(1):125-126. PubMed ID: 32474804
[No Abstract] [Full Text] [Related]
27. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
28. COVID-19: Some clinical questions after the first 4 months.
Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
[No Abstract] [Full Text] [Related]
29. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
Nasonov E; Samsonov M
Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514
[TBL] [Abstract][Full Text] [Related]
30. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Licciardi F; Giani T; Baldini L; Favalli EG; Caporali R; Cimaz R
Pediatr Rheumatol Online J; 2020 Apr; 18(1):35. PubMed ID: 32321540
[TBL] [Abstract][Full Text] [Related]
31. Possible mechanisms responsible for acute coronary events in COVID-19.
Sheth AR; Grewal US; Patel HP; Thakkar S; Garikipati S; Gaddam J; Bawa D
Med Hypotheses; 2020 Oct; 143():110125. PubMed ID: 32763657
[TBL] [Abstract][Full Text] [Related]
32. Case Report: Systemic Inflammatory Response and Fast Recovery in a Pediatric Patient With COVID-19.
Klocperk A; Parackova Z; Dissou J; Malcova H; Pavlicek P; Vymazal T; Dolezalova P; Sediva A
Front Immunol; 2020; 11():1665. PubMed ID: 32719688
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
34. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
Front Immunol; 2020; 11():1708. PubMed ID: 32754163
[TBL] [Abstract][Full Text] [Related]
35. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
36. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr Virus Versus Novel Coronavirus-Induced Hemophagocytic Lymphohistocytosis: The Uncharted Waters.
Amir R; Kichloo A; Singh J; Bhanot R; Aljadah M; Kumar A; Albosta MS; Solanki S
J Investig Med High Impact Case Rep; 2020; 8():2324709620950107. PubMed ID: 32787459
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
Med Clin (Barc); 2020 Aug; 155(4):159-161. PubMed ID: 32532461
[TBL] [Abstract][Full Text] [Related]
39. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
40. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Smetana K; Brábek J
In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]